November 29, 2017 6:03pm

As Capricor (CAPR) sprouted (+$0.13) wings that were clipped (day’s range of $2.01 - $2.48) on trial initiation approval which also accentuates its need for a financing to pay for it … don’t wait for the slide – SELL!

 

Just another emblematic move in the parabolic time horizon

 

Pre-open indications: 5 hits and 1 miss

 

How right does one have to be? You could and should be reading this review of the day’s share pricing activity?

Is the truth so hard to fathom – that’s why my readership has grown exponentially!


 

Wednesday’s results have implications to Thursday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

 

Henry’omics:

From the pre-open’s newsletter, “news is aphorismatic while volatility is killing the sector as retail investors are motivated to questioning the outlook motivating many to exit … Lately risk has no reward.”

As I had stated, “Lately, investors are beyond caring as the sector senses the year end while searching for any upside to profit or even exit.”

RegMed and cell therapy stocks, admittedly some of the worst performers of the year, took yet another big step back Wednesday to close sharply lower, led by a selloff of stem cell companies (NWBO, CYTX, KOOLO, and ATHX etc.).

Among companies that benefited from Monday were … CLLS (+$0.56), STML (+$0.50), FCSC (+$0.24), CLBS (+$0.05) and ADVM (+$0.03) …. and stayed up on TuesdayCLLS (+$0.05), STML (+$0.40) while some were admonished FCSC (-$0.15), CLBS (-$0.07) and ADVM (+$0.00) was flat ...

Following Monday’s downside, JUNO (-$1.63), QURE (-$0.85), RGNX (-$0.45), and BLCM (-$0.23); … Tuesday saw the coin flipped with further downside moves - JUNO (-$4.19), QURE (-$0.19), RGNX (-$1.00) while BLCM ($0.00) was flat

While on Wednesday, the same “players” CLLS (-$0.99), STML (+$0.10), FCSC (-$0.03), CLBS (-$0.14), ADVM (-$0.05), JUNO (-$2.51), QURE (-$0.19) and RGNX (-$1.45) continued the slide … while BLCM ($0.02) was up …

 

There is more than enough downside momentum ... lately it seems like a "freak-out" versus a break-down!

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The open was positive with an A/DL of 23/19 and 1 flats ;

·         The mid-day was negative with an A/DL of 19/22 and 2 flats;

·         The early close was negative with an A/DL of 18/22 and 3 flats;

 

Pre-open indications: 5 hits and 1 miss

  • BioLife Solutions (BLFS) closed up +$0.07 – hit;
  • bluebird bio (BLUE) closed up +$0.85 – miss;
  • Capricor (CAPR) closed up +$0.13 – hit;
  • Cesca Therapeutics (KOOL) closed down -$0.26 – hit;
  • Juno Therapeutics (JUNO) closed down -$2.51 – hit;
  • Pluristem (PSTI) closed up + $0.01 – hit;

 

 

Some of MY working trend lines or indications:

The greatest volume to the downside:  NWBO, CYTX, JUNO, MDXG and ATHX

Upside volume was weighted to:  CAPR, IMUC, XON, ONVO and BLUE

Biggest $ downside: JUNO (-$2.51), RGNX (-$1.45), CLLS (-$0.99), MDXG (-$0.34) and KOOL (-$0.26)

Largest $ upside:  BLUE (+$0.85), XON (+$0.60), ADRO (+$0.50), ONCE (+$0.34) and CAPR (+$0.13)

Flat:  AST, SGMO and RENE.L

 

 

Daily analytics:

Rotation was the theme of the day while the release of the Beige Book by the Fed had little impact on the market.

·         The Dow rose 95 points, or 0.4%, to 23,932, setting an intraday record.

·         The S&P 500 index edged down 2.2 points to 2,624 but eight of its 11 main sectors were trading higher.

·         The NASDAQ dropped 89 points, or 1.3%, to 6,823.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market; Wednesday traded at 10.70, up +6.68% …

  • Tuesday traded at 10.03, up +1.62% after Monday traded at 9.87, down 00.10% after Friday traded at 9.65, down -2.33% after Thursday was turkey day and last Wednesday traded at 9.98, up +1.54% …

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Wednesday was up +0.34%

·         Tuesday +1.57%

·         Monday -0.31%

·         Friday was up +0.04%

·         Thursday was holiday

·         Last Wednesday -0.13%

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Wednesday was down -0.01%

·         Tuesday +0.28%

·         Monday -0.70%

·         Friday was up +0.04%

·         Thursday was holiday

·         Last Wednesday was up +0.58%

 

 

The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %

·         Wednesday’s decliners ranged from -0.39% <AXGN -$0.10> to -12.33% <NWBO -$0.04> in 22 equities;

·         Tuesday’s decliners ranged from -0.19% <AXGN -$0.05> to -10.29% <KOOL -$0.36> in 23 equities;

·         Monday’s decliners ranged from -0.03% <BLUE -$0.05> to -11.18% <BSTG -$0.01> in 29 equities;

·         Friday’s decliners ranged from -0.31% <VTGN -$0.0027> to -0.17% <RGNX -$0.05> in 25 equities;

·         Thursday was turkey day

·         Last Wednesday’s decliners ranged from -0.03% <BLUE -$0.05> to -10.26% <IMUC -$0.035> in 16 equities;

Versus

 

… Look at the percentage’s (%) and spreads …

·         Wednesday’s gainers ranged from +0.21% <BLCM +$0.02> to +13.74% <BSTG +$0.008> in 19 equities;

·         Tuesday’s gainers ranged from +0.20% <CLLS +$0.05> to +5.79% <MDXG +$0.63> in 15 equities;

·         Monday’s gainers ranged from +0.71% <FATE +$0.03> to +17.24% <FCSC +$0.25> in 11 equities;

·         Friday’s gainers ranged from +0.11% <ONCE +$0.08> to +8% <NWBO +$0.02> in 24 equities;

·         Thursday was a holiday;

·         Last Wednesday’s gainers ranged from +0.80% <MESO +$0.04> to +12.90% <CYTX +$0.044> in 26 equities;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.